Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Preferred Dividend Payments (2016 - 2018)

Historic Preferred Dividend Payments for Alaunos Therapeutics (TCRT) over the last 3 years, with Q4 2018 value amounting to $342000.0.

  • Alaunos Therapeutics' Preferred Dividend Payments fell 9315.86% to $342000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $17.0 million, marking a year-over-year decrease of 1024.4%. This contributed to the annual value of $17.0 million for FY2018, which is 1024.4% down from last year.
  • Latest data reveals that Alaunos Therapeutics reported Preferred Dividend Payments of $342000.0 as of Q4 2018, which was down 9315.86% from $6.1 million recorded in Q3 2018.
  • In the past 5 years, Alaunos Therapeutics' Preferred Dividend Payments registered a high of $6.1 million during Q3 2018, and its lowest value of $342000.0 during Q4 2018.
  • Over the past 3 years, Alaunos Therapeutics' median Preferred Dividend Payments value was $4.9 million (recorded in 2017), while the average stood at $4.3 million.
  • As far as peak fluctuations go, Alaunos Therapeutics' Preferred Dividend Payments skyrocketed by 4153.45% in 2017, and later tumbled by 9315.86% in 2018.
  • Over the past 3 years, Alaunos Therapeutics' Preferred Dividend Payments (Quarter) stood at $3.5 million in 2016, then surged by 41.53% to $5.0 million in 2017, then plummeted by 93.16% to $342000.0 in 2018.
  • Its Preferred Dividend Payments stands at $342000.0 for Q4 2018, versus $6.1 million for Q3 2018 and $5.5 million for Q2 2018.